John Scholler

This paper develops a CAR T-cell targeting the mesothelin stump domain, showing comparable cytotoxicity and effectiveness against resistant tumors compared to standard anti-mesothelin CAR T-cells.

This study develops DR5-targeted CAR-T cells that kill solid tumors and MDSCs, enhance CD8+ T cell activity, and show minimal toxicity in preclinical models.

This study shows that IL18-expressing CAR T cells enhance antitumor immunity, T cell proliferation, and costimulation, while reducing GVHD risk through a novel strategy.